Articles related to DRY EYE DISEASE (DED)

As the optometry field advances, newer, more innovative medications are being introduced for the management of dry eye disease and Demodex blepharitis. These developments pave the way for more personalized and successful patient care.

Aldeyra’s reproxalap shows considerable promise as a breakthrough treatment for ocular surface inflammatory conditions, highlighting its potential in addressing a significant unmet need in the field of optometry. Explore these groundbreaking clinical trial results.

Unveiling fresh perspectives on dry eye disease treatment through a comprehensive study that scrutinizes tear proteomic analysis and clinical parameters. In a breakthrough study on dry eye disease (DED) treatment, researchers employed tear proteomic analysis to identify potential tear biomarkers. They combined this with a rigorous examination of clinical parameters. Data was gathered from a double-blinded, national multicenter clinical trial involving 80 DED patients. The subjects underwent treatment with either 0.1% cyclosporine, 0.05% cyclosporine, or 3% diquafosol eye drops. Observations took place at four-week intervals, lasting for 12 weeks. Key metrics observed included tear break-up time, corneal erosion, conjunctival erosion, and symptom assessment in dry eye scores. This data was then correlated with protein expressions identified through the proteomic analysis. Interestingly, the same seven proteins were identified in all treatment groups. These proteins were noted to be downregulated following treatment. At the 12-week mark, all clinical parameters demonstrated a significant improvement from the baseline. However, among the groups, no significant differences in values were recorded, except in the case of corneal erosion. The latter parameter significantly improved after treatment with both cyclosporine concentrations, as compared to the diquafosol group. However, the correlation of these proteins with the clinical parameters was […]

More sedentary time was associated with a higher risk of dry eye disease (DED), particularly for people whose physical activity (PA) levels were below WHO limits. Screen use, however, could account for the observed link and should be emphasized as a potential main confounder since there was no significant association when computer-intensive sitting time was eliminated.

Dry eye disease (DED), ocular surface disease (OSD), and other cornea and anterior segment diseases can cause patients to experience a diverse range of symptoms. The cornea is the most densely innervated tissue and is therefore an important target for therapeutics and research. Transient receptor potential (TRP) channels are signaling channels that play roles in signaling physiological processes, and TRP melastatin member 8 (TRPM8) is a cold-sensing receptor found on nerve endings of the ophthalmic branch of the trigeminal nerve. TRPM8 channels sense cooling changes in corneal temperature and are activated by evaporative cooling and hyperosmolarity, leading to stimulation of tear production, which may be why eyes water on cold days and in patients with dry eye. Understanding the interaction between symptoms, ocular healing, and dysfunctions that occur in this process can help optometrists care for their patients more effectively.

When the eyelid shifts to an abnormal anatomic position, this is referred to as eyelid malposition. Sixty percent of symptomatic dry eye patients have compromised lid closure due to eyelid malposition. Regardless of the type of eyelid malposition, hallmark symptoms such as foreign body sensation, excessive tearing, redness, and ocular irritation can all occur. There are distinctions between signs and symptoms. Although symptoms can help identify eyelid malposition, a careful objective examination of the eyelids is essential for determining the malposition and recommending the best treatment.